Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer • Medical Oncology
What is your approach to metastatic choroidal melanoma with systemic metastases outside of a clinical trial?
NCCN guidelines recommend both single agent Pembro and/or Ipi/Nivo as first line options. How would you choose between the two? In case of the latter, would your choice of Ipilimumab Q6 weeks vs Q3 weeks be guided by autoimmune toxicity?
Answer from: Medical Oncologist at Academic Institution
I often consider local therapy for systemic mets with radiation (Mostly SBRT), embolization, ablation, Y-90 etc. In very selected patients surgery. If widespread disease or not a candidate for local therapy then I favor PD-1 inhibitors over ipi to start due to toxicity. Both agents have limited acti...
Sign in or Register to read more